When tested against a relatively low burden of flank-engrafted PC3-PSMA prostate tumor cells, PRDM1 KO PSMA CAR T-cells exhibited a modest enhancement of tumor control compared to control CAR T-cells (fig. This evidence concerns the gene PRDM1 and prostate neoplasm.